These results suggested that plasmatic levels of HSP90α at diagnosis is a favorable predictor for PFS and OS in advanced lung cancer patients treated with PD-1/PD-L1 inhibitors plus chemotherapy. Here, PDCD1 is linked to lung carcinoma.